Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(18):1352-1353; doi:10.1093/jnci/94.18.1352
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benowitz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 18, 1352-1353, September 18, 2002
© 2002 Oxford University Press

NEWS

Big Business: When Wall Street and Cancer Research Collide

Steve Benowitz

The first 10% of the full text of this article appears below.

When scientists at Cell Therapeutics Inc. (CTI), a Seattle-based company that specializes in developing cancer drugs, submitted several abstracts in December for the 2002 meeting of the American Society of Clinical Oncology, the scientists could not have known the intense scrutiny they were going to face. Between April and May of this year, officials at the company fielded some 200 calls from investors and financial media asking for comments on rumors that one of CTI’s signature products, Xyotax, a paclitaxel-related drug for ovarian and lung cancer, was too toxic for patients.

This wasn’t supposed to happen.

ASCO, the nation’s preeminent organization of clinical oncologists, last year announced a new policy—which included a confidentiality agreement—for access to abstracts on its Web site for its annual meeting. The meeting, which draws thousands of cancer specialists every year, is seen as a key gathering . . . [Full Text of this Article]

Big Business

Information Leak


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?